Aoibheann Conneely
Research Subjects
Aoibheann Conneely has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Bettina Korn
Department of Nursing, St James's Hospital , Dublin
1 shared publicationCaroline Burke
Palliative Medicine, Milford Care Centre, Castletroy, Limerick, Ireland
1 shared publicationCiara Anderson
Department of Infectious Diseases, St James's Hospital , Dublin
1 shared publicationCiaran Bannan
Department of Infectious Diseases, St James's Hospital , Dublin
1 shared publication- Ed Duffy
Palliative Medicine, Milford Care Centre, Castletroy, Limerick, Ireland
1 shared publication - Eva Jones
St. James’ Hospital, Dublin, Ireland
1 shared publication
Latest Publications
- Open Access
- 30 October 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (11)
Factors Influencing Antimicrobial Choice and Duration During the Last Month of Life in Hospitalized Patients
Background: Antimicrobial prescribing in patients approaching end of life is complex. We aimed to describe antimicrobial use in the final 4 weeks of life among hospitalized patients and identify factors associated with antimicrobial consumption. Methods: We conducted a retrospective review of antimicrobial use among inpatients during their last 4 weeks of life in a tertiary Irish hospital. Data collected included antimicrobial agents and duration of therapy, microbiological sampling, infection services input, palliative care services input, patient demographics, frailty scores, and markers of inflammation. Univariate analysis and multivariable linear regression were used to assess factors associated with antimicrobial-free time before death. Results: Two hundred and fifty-eight patients were included, with 91% receiving antimicrobials during the study period. Only 36% had a presumed infection at the time of admission. Antimicrobial use was characterized by broad-spectrum agents, did not correlate with culture results, and had a median duration (interquartile range) of 10.5 (5–18) days. Palliative care consultation (P = .004) and longer length of stay (P < .0001) were associated with a longer antimicrobial-free interval before death. Within the antimicrobial cohort, 26% developed acute kidney injury. Cessation of antimicrobial therapy often occurred late, with 40% of patients receiving antimicrobial therapy within 24 hours of death. Conclusions: There was a high burden of antimicrobial use in patients nearing the end of life, characterized by broad-spectrum, empiric therapy, often continued until hours before death. We recommend expansion of antimicrobial surveillance and collaboration between infection and palliative care services in order to optimize and rationalize antimicrobial prescribing in patients approaching end of life.
- 30 October 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (11)
Open AccessFactors Influencing Antimicrobial Choice and Duration During the Last Month of Life in Hospitalized Patients
Background: Antimicrobial prescribing in patients approaching end of life is complex. We aimed to describe antimicrobial use in the final 4 weeks of life among hospitalized patients and identify factors associated with antimicrobial consumption. Methods: We conducted a retrospective review of antimicrobial use among inpatients during their last 4 weeks of life in a tertiary Irish hospital. Data collected included antimicrobial agents and duration of therapy, microbiological sampling, infection services input, palliative care services input, patient demographics, frailty scores, and markers of inflammation. Univariate analysis and multivariable linear regression were used to assess factors associated with antimicrobial-free time before death. Results: Two hundred and fifty-eight patients were included, with 91% receiving antimicrobials during the study period. Only 36% had a presumed infection at the time of admission. Antimicrobial use was characterized by broad-spectrum agents, did not correlate with culture results, and had a median duration (interquartile range) of 10.5 (5–18) days. Palliative care consultation (P = .004) and longer length of stay (P < .0001) were associated with a longer antimicrobial-free interval before death. Within the antimicrobial cohort, 26% developed acute kidney injury. Cessation of antimicrobial therapy often occurred late, with 40% of patients receiving antimicrobial therapy within 24 hours of death. Conclusions: There was a high burden of antimicrobial use in patients nearing the end of life, characterized by broad-spectrum, empiric therapy, often continued until hours before death. We recommend expansion of antimicrobial surveillance and collaboration between infection and palliative care services in order to optimize and rationalize antimicrobial prescribing in patients approaching end of life.
- 2 September 2021
- Published by BMJ in BMJ Supportive & Palliative Care
- Vol. 13 (3) , 291-297
Red cell transfusion benefits in oncology, haematology and palliative medicine populations: a narrative review
Due to the heterogenous nature of the palliative medicine patient population, assessment of benefit, and thus choice of appropriate patient for consideration of transfusion, can be challenging. This can be confounded by the use of both liberal and restrictive transfusion thresholds. The multifactorial nature of many symptoms of anaemia, particularly in patients with advanced malignancy, can further complicate. As such, there is a paucity of data supporting the subjective, objective and clinical benefit of red cell transfusion in the palliative medicine setting. This narrative review summarises the research and evidence surrounding the benefits of red cell transfusion, with a particular emphasis on the oncological, haematological and palliative medicine population. There is a lack of a validated, reproducible patient-reported outcome measures (PROM) to assess response to red cell transfusions in the palliative medicine population with outcome measures varying from objective improvement in haemoglobin level post-transfusion, to subjective response in primary symptom(s). Further investigation is required regarding the development of effective PROMs assessing response to red cell transfusion in the palliative medicine population, to ensure judicious use of this scarce and valuable resource.
- 2 September 2021
- Published by BMJ in BMJ Supportive & Palliative Care
- Vol. 13 (3) , 291-297
Red cell transfusion benefits in oncology, haematology and palliative medicine populations: a narrative review
Due to the heterogenous nature of the palliative medicine patient population, assessment of benefit, and thus choice of appropriate patient for consideration of transfusion, can be challenging. This can be confounded by the use of both liberal and restrictive transfusion thresholds. The multifactorial nature of many symptoms of anaemia, particularly in patients with advanced malignancy, can further complicate. As such, there is a paucity of data supporting the subjective, objective and clinical benefit of red cell transfusion in the palliative medicine setting. This narrative review summarises the research and evidence surrounding the benefits of red cell transfusion, with a particular emphasis on the oncological, haematological and palliative medicine population. There is a lack of a validated, reproducible patient-reported outcome measures (PROM) to assess response to red cell transfusions in the palliative medicine population with outcome measures varying from objective improvement in haemoglobin level post-transfusion, to subjective response in primary symptom(s). Further investigation is required regarding the development of effective PROMs assessing response to red cell transfusion in the palliative medicine population, to ensure judicious use of this scarce and valuable resource.